Ovation Science Licensee Launches Innovative Transdermal Cannabis Products in Pennsylvania

VANCOUVER, BC / ACCESSWIRE / December 4, 2024 / (CSE:OVAT)(OTC PINK:OVATF) – Ovation…

Cardiol’s Favorable Phase 2 Results Set the Table for Advanced Clinical Trials

Cardiol Therapeutics Inc. (Nasdaq: CRDL) (TSX: CRDL) recently presented excellent results from…

Cardiol Therapeutics’ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the…

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1…

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Toronto, Ontario–(Newsfile Corp. – September 24, 2024) – Cardiol Therapeutics Inc. (NASDAQ:…

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Full clinical data will be reported in an oral presentation at the…

Clearmind Medicine Granted Patent Approval in Hong Kong

Vancouver, Canada, June 28, 2024  — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind”…